4D Molecular Therapeutics, Inc. (4DMT), is a trailblazing clinical-stage biopharma enterprise that is pioneering genetic therapies with a bold vision to transform lives affected by severe genetic diseases. Founded in 2013 and headquartered in Emeryville, California, 4DMT is tackling previously untreatable genetic disorders with transformative next-generation therapeutics.
A powerhouse of industry-leading expertise in vector discovery, gene therapy, biologics development, and manufacturing, 4DMT's focus is on creating precisely targeted and disease-specific delivery vectors for gene therapy. Their unique Therapeutic Vector Evolution platform generates powerful adeno-associated virus (AAV) vectors which deliver genes directly into the cells of patients.
At the heart of 4D Molecular Therapeutics’ is an innovative platform, known as Therapeutic Vector Evolution. This revolutionary approach in genetic medicine allows 4DMT to generate and optimize a personalized genetic therapy vector for any disease. The platform gives 4DMT the unprecedented capability to design corrective gene vectors precisely, choosing from over a hundred million vector sequences. It further enables tailoring vectors for particular patient populations, with specific therapeutic aims like complex retinal diseases, certain muscle diseases, and numerous others.
4DMT's core strategy relies on focused therapeutic areas: ophthalmology, cardiology, and pulmonology, and has developed several leading programs in these therapeutic areas. The company's prime product candidates include 4D-125 for X-linked retinitis pigmentosa (XLRP), 4D-110 for choroideremia, both retinal diseases, part of its robust ophthalmology portfolio.
4DMT also leverages collaborations and partnerships with leading pharmaceutical companies and research institutions to maximize its reach and impact. Its strategic collaboration with Roche for 4D-125 and 4D-110 is one such example, illustrating the firm’s ambition and credibility in the market.
Indeed, 4D Molecular Therapeutics is redefining the boundaries of genetic therapy. By unlocking the full potential of gene therapy through its innovative platform, it is ushering in a new era of precision medicine aimed at offering hope and improved quality of life for patients with severe genetic diseases. Its cutting-edge science, unique therapeutic design, and unwavering dedication to patients truly set 4DMT apart in the world of biopharmaceuticals.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Kirn David sold 58,333 shares of 4D Molecular Therapeutics (FDM) on September 14, 2026, at a price of $13.90 per share. This open-market sale represented approximately 7.1% of his previous holdings in the company. Following the transaction, Kirn David retained 767,486 shares of 4D Molecular Therapeutics.
Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) dropped 3.7% on Friday, trading at around $15.50 on lower-than-average volume. Despite a "Moderate Buy" consensus rating and a $29.62 average price target from analysts, the company reported a quarterly loss of $1.04 per share, missing estimates, though revenue exceeded expectations. Insider selling also occurred, with 200,496 shares sold for approximately $2.24 million in the last quarter.
4D Molecular Therapeutics (NASDAQ:FDMT) recently hit a new 52-week high of $15.03, closing at $14.55, but the company remains unprofitable with a negative EPS. While analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $29.62, some insiders have been selling shares. Hedge funds have also been adjusting their positions, with institutional investors owning 99.27% of the stock.